As the global population and its demand for seafood increases more of our fish will come from aquaculture. Farmed Atlantic salmon are a global commodity and, as an oily fish, contain a rich source of the health promoting long-chain omega-3 fatty acids, eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids. Replacing the traditional finite marine ingredients, fishmeal and fish oil, in farmed salmon diets with sustainable alternatives of terrestrial origin, devoid of EPA and DHA, presents a significant challenge for the aquaculture industry. By comparing the fatty acid composition of over 3,000 Scottish Atlantic salmon farmed between 2006 and 2015, we find that terrestrial fatty acids have significantly increased alongside a decrease in EPA and DHA levels. Consequently, the nutritional value of the final product is compromised requiring double portion sizes, as compared to 2006, in order to satisfy recommended EPA + DHA intake levels endorsed by health advisory organisations. Nevertheless, farmed Scottish salmon still delivers more EPA + DHA than most other fish species and all terrestrial livestock. Our findings highlight the global shortfall of EPA and DHA and the implications this has for the human consumer and examines the potential of microalgae and genetically modified crops as future sources of these important fatty acids.

The omega-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFA), eicosapentaenoic (EPA, 20:5n-3) and docosahexaenoic (DHA, 22:6n-3) acids, are well accepted as being essential components of a healthy, balanced diet, having beneficial effects on development and in mitigating a range of pathological conditions. However, their global supply from all the traditional sources of these nutrients is insufficient to satisfy human nutritional requirements. For two decades there has been considerable research carried out into all possible alternatives to the main sources of n-3 LC-PUFA, marine fish oil and fishmeal, driven largely by the aquaculture sector, as both the major user and provider of EPA and DHA. In the last few years these efforts have focused increasingly on the development of entirely new supplies of n-3 LC-PUFA produced de novo. Recently, this has resulted in various new sources of EPA and/or DHA that are already available or likely to available in the near future. In this short review, we briefly summaries the current gap between supply and demand of EPA and DHA for human requirements, the role of aquaculture in providing n-3 LC-PUFA to human consumers, the range of potential novel sources, and suggest how these new products could be used effectively. We conclude that all the new sources have potentially important roles to play in increasing the supply of n-3 LC-PUFA so that they are available more widely and in higher concentrations providing more options and opportunities for human consumers to obtain sufficient EPA and DHA to support more healthy, balanced diets.

For humans a daily intake of up to 500 mg omega-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFA) is recommended, amounting to an annual requirement of 1.25 million metric tonnes (mt) for a population of 7 billion people. The annual global supply of n-3 LC-PUFA cannot meet this level of requirement and so there is a large gap between supply and demand. The dietary source of n-3 LC-PUFA, fish and seafood, is increasingly provided by aquaculture but using fish oil in feeds to supply n-3 LC-PUFA is unsustainable. Therefore, new sources of n-3 LC-PUFA are required to supply the demand from aquaculture and direct human consumption. One approach is metabolically engineering oilseed crops to synthesize n-3 LC-PUFA in seeds. Transgenic Camelina sativa expressing algal genes was used to produce an oil containing n-3 LC-PUFA to replace fish oil in salmon feeds. The oil had no detrimental effects on fish performance, metabolic responses or the nutritional quality of the fillets of the farmed fish.

The replacement of fish oil (FO) with a DHA-rich Schizochytrium sp. algal meal 16 (AM) at two inclusion levels (11% and 5.5% of diet) was tested in Atlantic salmon 17 post-smolts compared to fish fed a FO diet of northern (NFO) or southern hemisphere 18 (SFO) origin. Fish were preconditioned prior to the 19-week experimental feeding 19 period to reduce long-chain polyunsaturated fatty acid (LC-PUFA) and persistent 20 organic pollutant levels (POPs). Dietary POP levels differed significantly between 21 treatments in the order of NFO>SFO>11AM/5.5AM and were subsequently reflected 22 in the flesh. Fish fed the 11AM diet contained similar DHA levels (g.100g -1 flesh) to 23 FO-fed fish, despite percentage differences. However, the low levels of EPA in the 24 diets and flesh of algal-fed fish compromised the overall nutritional value to the final 25 consumer. Nevertheless, further developments in microalgae culture offer a 26 promising alternative lipid source of LC-PUFA to FO in salmon feeds that warrants 27 further investigation. 28 29

Omega-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFA) are essential components of the diet of all vertebrates. The major dietary source of n-3 LC-PUFA for humans has been fish and seafood but, paradoxically, farmed fish are also reliant on marine fisheries for fish meal and fish oil (FO), traditionally major ingredients of aquafeeds. Currently, the only sustainable alternatives to FO are vegetable oils, which are rich in C18 PUFA, but devoid of the eicosapentaenoic (EPA) and docosahexaenoic acids (DHA) abundant in FO. Two new n-3 LC-PUFA sources obtained from genetically modified (GM) Camelina sativa containing either EPA alone (ECO) or EPA and DHA (DCO) were compared to FO and wild-type camelina oil (WCO) in juvenile sea bream. Neither ECO nor DCO had any detrimental effects on fish performance, although final weight of ECO-fed fish (117 g) was slightly lower than that of FO- and DCO-fed fish (130 and 127 g, respectively). Inclusion of the GM-derived oils enhanced the n-3 LC-PUFA content in fish tissues compared to WCO, although limited biosynthesis was observed indicating accumulation of dietary fatty acids. The expression of genes involved in several lipid metabolic processes, as well as fish health and immune response, in both liver and anterior intestine were altered in fish fed the GM-derived oils. This showed a similar pattern to that observed in WCO-fed fish reflecting the hybrid fatty acid profile of the new oils. Overall the data indicated that the GM-derived oils could be suitable alternatives to dietary FO in sea bream.